New Journey Health Technology Group (002219) Fundamentals 2026 — P/E 247.5x, Revenue Analysis | SniperIQ
New Journey Health Technology Group (002219) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥6.8B, trading at ¥1.98 on the SHZ. This SniperIQ fundamentals page covers New Journey Health Technology Group's valuation (P/E 247.5x, P/B 3.4x), profitability (net margin 0.8%), revenue (¥3.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is New Journey Health Technology Group's market cap?
New Journey Health Technology Group (002219) has a market capitalization of approximately ¥6.8B, trading at ¥1.98 on the SHZ. Market cap moves with the live share price.
What is New Journey Health Technology Group's P/E ratio?
New Journey Health Technology Group's trailing twelve-month P/E ratio is 247.5x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is New Journey Health Technology Group?
New Journey Health Technology Group runs a net profit margin of 0.8%, a gross margin of 29.4%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does New Journey Health Technology Group generate?
New Journey Health Technology Group reported revenue of ¥3.1B for fiscal year 2025, with net income of ¥31M and earnings per share (EPS) of 0.0094. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does New Journey Health Technology Group pay a dividend?
New Journey Health Technology Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is New Journey Health Technology Group financially healthy?
New Journey Health Technology Group carries a debt-to-equity ratio of 1.13x and a current ratio of 0.53x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is New Journey Health Technology Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For New Journey Health Technology Group (002219) the key facts are: market cap ¥6.8B, P/E 247.5x, revenue ¥3.1B, 52-week range 1.69-2.97. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track New Journey Health Technology Group's full fundamentals live
Get New Journey Health Technology Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.